Journal of Pharmaceutical Investigation

The Korean Society of Pharmaceutical Sciences and Technology (한국약제학회)
권호 표지
DOI QR코드

DOI QR Code

Drug Interaction between Ketoconazole and Paclitaxel in Rats

케토코나졸과 파크리탁셀과의 약물상호작용

  • Published : 2003.09.20
Download PDF
⟨ Previous Next ⟩

Abstract

The purpose of this study was to investigate the effect of ketoconazole (20 mg/kg) on the pharmacokinetic parameters and the bioavailability of paclitaxel (40 mg/kg) orally coadministered in rats. The plasma concentration of paclitaxel in combination with ketoconazole was significantly (p<0.05) increased from 8 hr to 24 hr compared to that of control. Area under the plasma concentration-time curve (AUC) of paclitaxel with ketoconazole was significantly (coadministration p<0.05, pretreatment p<0.0l) higher than that of control. Peak concentration $(C_{max})$ of paclitaxel pretreated with ketoconazole were significantly (p<0.05) increased compared to that of control. Time to peak concentation $(T_{max})$ of paclitaxel pretreated with ketoconazole were significantly (p<0.05) shorter than that of control. Half-life at elimination phase $(t_{1/2{\beta}})$ of paclitaxel pretreated with ketoconazole was significantly (p<0.05) prolonged compared to that of control. Based on these results, it might be due to both inhibition of the enzyme cytochrome P450 and p-glycoprotein, which engaged in paclitaxel absorption and metabolism in liver and gastrointestinal mucosa.

Keywords

References

  1. A.E. Mathew, M.R. Mejillano, J.P. Nath, R.H. Himes and V.J. Stella, Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity, J. Med. Chem., 35(1), 145-151 (1992) https://doi.org/10.1021/jm00079a019
  2. P.M. Chaudhary and I.B. Robinson, Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell, 66, 85-94 (1991) https://doi.org/10.1016/0092-8674(91)90141-K
  3. J.A. Endicott and V. Ling, The biochemistry of P-glycoprotein- mediated multidrug resistance, Annu. Rev. Biochem., 58, 137-171 (1989) https://doi.org/10.1146/annurev.bi.58.070189.001033
  4. A. Rahman, K.R. Korzekwa, J. Grogan, F.J. Gonzalez and J.W. Harris, Selective biotransformation of taxol to 6-hydroxytaxol by human cytochrome P450 2C8., Cancer Res., 54, 5543-5548 (1994)
  5. D.S. Sonnichsen, Q. Liu, E.G, Schuetz, J.D. Schuetz, A. Pappo and M.V. ReIling, Variability in human cytochrome P450 paclitaxel metabolism., J. Pharmacol. Exp. Ther., 275, 566-571 (1995)
  6. T. Walle, Short communication, Taxol metabolism in rat hepatocytes. Biochem. Pharmacol., 46(9), 1661-1664 (1993) https://doi.org/10.1016/0006-2952(93)90336-U
  7. D.S. Sonnichsen and M.V. ReIling, Clinical Pharmacokinetics of Paclitaxel, Clin. Phannacokinet., 27(4), 256-269 (1994) https://doi.org/10.2165/00003088-199427040-00002
  8. G.A. Fisher and B.I. Sikic, Clinical studies with modulators of multidrug resistance. Hematol. Oncol. Clin. North Am., 9(2), 363-382 (1995)
  9. E. Hofsli and J.N. Meyer, Reversal of multidrug resistance by lipophilic drugs, Cancer Res., 50, 3997-4002 (1990)
  10. L.J. Bain, J.B. McLanchlan and G.A. LeBanc, Structureactivity relationship for xenobiotic transport substrates and inhibitory ligands of p-glycoprotein, Enviromental Health Perspectives, 105(8), 812-818 (1997) https://doi.org/10.2307/3433698
  11. T. Cresteil, B. Monsarrat, P. Alvinerid, J.M. Treluyer, I. Vieira and M. Wright. Taxol metabolism by human liver microsomes, identification of cytochrome P450 isozymes involved in its biotransformation, Cancer Res., 54, 386-395 (1994)
  12. J.W. Harris, A. Rahman, B.R. Kim, F.P. Guengerich and J.M. Collins, Metabolism of taxol by human hepatic microsomes and liver slices, participation of cytochrome P450 3A4 and an unknown P450 enzyme, Cancer Res., 54, 4026-4031 (1994)
  13. E.J. Wang, K. Lew, C.N. Casciano, R.P. Clement and W.W. Johnson, Interaction of common azole antifungals with P glycoprotein, Antimicrab. Agents Chemother, 46(1), 160-165 (2002) https://doi.org/10.1128/AAC.46.1.160-165.2002
  14. E.J. Wang, C.N. Casciano, R.P. Clement and W.W Johnson, HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein, Pharm. Res., 18, 800-806 (2001) https://doi.org/10.1023/A:1011036428972
  15. I. Hsu, S.A. Spinler and N.E. Johnson, Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia, Ann. Pharmacother., 29, 743-759 (1995) https://doi.org/10.1177/106002809502907-818
  16. A. Bohme, A. Ganser and D. Hoelzer, Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult, ALL. Ann. Hematol., 71, 311-312 (1995) https://doi.org/10.1007/BF01697985
  17. S. Gupta, J. Kim and S. Gollapudi, Reversal of daunorubicin resistance in P388/ADR cells by itraconazole, J. Clin. Investig., 87, 1467-1469 (1991) https://doi.org/10.1172/JCI115154
  18. G. Vreugdenhil, J.M. Raemaekers, B.J. Dijke, van and B.E. Pauw, de Itraconazole and multidrug resistance, possible effects on remission rate and disease-free survival in acute leukemia, Ann. Hematol., 67, 107-109 (1993) https://doi.org/10.1007/BF01701730
  19. K.M. Kaukonen, K.T. Olkkola and P.J. Neuvonen, Itraconazole increases plasma concentrations of quinidine, Clin. Pharmacol. Ther., 62, 510-517 (1997) https://doi.org/10.1016/S0009-9236(97)90046-1
  20. K.M. Jalava, J. Partanen and P.J. Neuvonen, Itraconazole decreases renal clearance of digoxin, Ther. Drug Monit., 19, 609-613 (1997) https://doi.org/10.1097/00007691-199712000-00001
  21. J.M. Poirier and G. Cheymol, Optimisation of itraconazole therapy using target drug concentrations, Clin. Pharmacokinet., 35, 461-473 (1998) https://doi.org/10.2165/00003088-199835060-00004
  22. D. Debruyne, Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses, Clin. Pharmacokinet., 33, 52-77 (1997) https://doi.org/10.2165/00003088-199733010-00005
  23. K. Venkatakrishnan, L.L. von Moltke and D.J. Greenblatt, Effects of the antifungal agents on oxidative drug metabolism, clinical relevance, Clin. Pharmacokinet., 38, 111-180 (2000) https://doi.org/10.2165/00003088-200038020-00002
  24. J. Combalbert, I. Fabre and G. Fabre, et al., Metabolism of cyclosprrine A, IV : purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450A gene subfamily, Drug Metab. Disprs., 17, 197-207 (1989)
  25. T. Kronbach, V. Fischer and U.A. Meyer, Cyclosprrine metabolism in human liver, identification of a cytochrome P450 gene family as the major cyclosporine with other drugs, Clin. Pharmacol. Ther., 43, 630-635 (1988) https://doi.org/10.1038/clpt.1988.87
  26. J.C. Korars, P. Schmiedlin-Ren, J.D. Cchuetz, C. Fang and P.B. Watkins, Identification of rifampin-inducible P450A4 (CYP3A4) in human small bowel enterocytes, J. Clin. Invest., 90, 1871-1878 (1992) https://doi.org/10.1172/JCI116064
  27. J.C. Korars, W.M. Awni, P.M. Merion and P.B. Watkins, Firstpass metabolism of cyclosporin by the gut, Lancet, 338, 1488-1490 (1991) https://doi.org/10.1016/0140-6736(91)92302-I
  28. D.Y. Gomez, V.J. Wacher, S.J. Tomlanovich, M.F. Hebert and L.Z. Benet, The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine, Clin. Pharmacol. Ther., 58(1), 15-19 (1995) https://doi.org/10.1016/0009-9236(95)90067-5
  29. K.M. Kaukonen, K.T. Olkkola and P.J. Neuvonen, Itraconazole increases plasma concentrations of quinidine, Clin. Pharmacol. Ther., 62(5), 510-517 (1997) https://doi.org/10.1016/S0009-9236(97)90046-1
  30. N. Manrin, J. Catalin, M.F. Blachon and A. Durand, Assay of paclitaxel (Taxol) in plasma and urine by High Performance Liquid Chromatogrphy, J. Chromato. B., 709, 281-288 (1998) https://doi.org/10.1016/S0378-4347(98)00060-7
  31. H. Mase, M. Hiraoka and F. Suzuki, Determination of New Anticancer Drug, Paclitaxel, in Biological Fluids by High Performance Liquid Chromatography, Yakugaku. Zasshi., 114(5), 351-355 (1994) https://doi.org/10.1248/yakushi1947.114.5_351
  32. K. Yamaoka, Y. Tanigawara, T. Nakagawa and T. Uno, A pharmacokinetics analysis program for microcomputer, J. Pham. Dyn., 4, 79-883 (1981)